Dr Reddys Laboratories opened higher at ₹1,230.90, compared with its previous close of ₹1,229.40. During today's session, the stock has traded between ₹1,223.30 and ₹1,250.70, with an average traded price of ₹1,242.51. It is currently showing an upward intraday trend.
An investment of ₹10,000 made 5 years ago in Dr Reddys Laboratories is now worth
₹ 12,627.00
giving a profit of
₹ 2,627.00 (26.27%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
+10.60 (+0.86%)
Day High
₹1,250.70
Day Low
₹1,223.30
Day Open
₹1,230.90
Prev Close
₹1,229.40
Volume
24,17,763
Value Traded
₹300.41 Cr
1W Return
3.08%
1M Return
6.39%
3M Return
-0.35%
6M Return
0.63%
1Y Return
-1.93%
Market Cap (₹ Cr.)
1,03,500
PE Ratio
32.30
PB Ratio
2.70
Dividend Yield
0.65%
ROE
10.87%
ROCE
13.94%
Book Value (₹)
456.14
Face Value (₹)
1.00
EPS (TTM)
5.33
Industry PE
-
Beta
-
Debt to Equity
-
1 Week
3.08%
6 Week
-
1 Month
6.39%
3 Month
-0.35%
9 Month
2.02%
Dr Reddy's Q2FY27 Results: Earnings call scheduled for Oct 23 at 7:30 pm
Dr. Reddy's Laboratories will release Q2FY27 results on October 23, 2026. Earnings call scheduled for 19:30 pm IST (10:00 am ET) on the same day. Audio recording and transcript of the call will be available on the company website. Registration for the webinar is mandatory for participants.
6 days agoDr Reddy's Labs subsidiary receives $32,350 IRS penalty for tax error
Dr Reddy's Laboratories' US subsidiary DRL Inc received a $32,350.20 IRS penalty. Penalty issued for misclassification of fiscal year reference in tax payment. Transcript dated September 25, 2026, was received by the subsidiary on October 2, 2026. Company states no material impact on financials or operations from the fine.
10 days agoDr Reddys to host Nomura for in-person group meet in Hyderabad
Dr Reddys Laboratories to hold in-person group meet with Nomura. Meeting scheduled for September 25, 2026, in Hyderabad. Session runs from 11:00 am to 2:00 pm IST. Disclosure made under SEBI Regulation 30.
22 days agoDr. Reddy's signs exclusive deal to market Takeda's Qdenga dengue vaccine
Dr. Reddy's secures exclusive rights to distribute Takeda's Qdenga vaccine in India's private sector. Qdenga is India's first approved dengue vaccine, authorized by CDSCO for ages 4-60 in July 2026. The deal involves no upfront payments or milestones, limiting financial risk for Dr. Reddy's. Vaccine availability expected in H1 2027, addressing an 11-fold rise in dengue cases over two decades.
25 days agoDr Reddys schedules analyst and institutional investor meetings for September
Dr Reddys Laboratories schedules two investor meetings in September 2026. First meet with ICICI Securities on September 17 in Hyderabad (in-person). Second virtual group meet with Bank of America on September 24. Disclosures made under SEBI LODR Regulation 30.
1mo agoDr. Reddy's Laboratories wins U.S. FDA approval for rituximab biosimilar
Dr. Reddy's Laboratories secured U.S. FDA approval for its rituximab biosimilar on August 1, 2026, following a successful inspection of its Hyderabad facility. Fresenius Kabi will exclusively commercialize the drug in the United States, adding to Dr. Reddy's existing presence in Europe, India, and emerging markets. The approval validates the company's capabilities in complex biologics development.
2mo ago| Contract | Days to Expiry | LTP | Change | Change % | Volume | OI | OI Chg % |
|---|---|---|---|---|---|---|---|
| DRREDDY OCT FUT | 15 | 1,243.00 | 8.80 | 0.71 | 19,05,625 | 2,09,65,000 | 0.90 |
| DRREDDY NOV FUT | 42 | 1,241.20 | 9.80 | 0.80 | 2,06,250 | 16,92,500 | 5.91 |
| DRREDDY DEC FUT | 78 | 1,236.20 | 7.10 | 0.58 | 2,500 | 18,125 | 7.41 |
| Stock | LTP | Change % | Market Cap (Cr.) | PE | 1Y Return |
|---|---|---|---|---|---|
| ₹1,770.70 | +0.61% | ₹4,24,850.24 | 34.83 | +5.97% | |
| ₹9,285.00 | -1.50% | ₹2,46,487.58 | 85.12 | +43.41% | |
| ₹4,642.90 | -0.84% | ₹1,76,600.99 | 82.55 | +31.42% | |
| ₹1,132.50 | -0.17% | ₹1,12,967.31 | 24.74 | +14.00% | |
| ₹2,059.40 | -0.47% | ₹1,11,271.90 | 102.63 | +134.89% | |
| ₹1,329.60 | +1.40% | ₹1,07,412.86 | 31.62 | -14.87% | |
| ₹2,372.00 | -1.17% | ₹97,974.30 | 47.92 | -3.57% | |
| ₹1,684.60 | -1.31% | ₹96,928.16 | 26.40 | +49.04% | |
| ₹1,953.60 | +0.96% | ₹89,336.17 | 16.03 | -0.29% | |
| ₹2,265.30 | -0.78% | ₹63,932.35 | 35.82 | +16.81% | |
| ₹5,250.00 | +0.86% | ₹62,771.63 | 28.34 | -3.75% | |
| ₹351.00 | +1.34% | ₹57,202.26 | 134.86 | -0.69% |
An investment of ₹10,000 made 5 years ago in Dr Reddys Laboratories is now worth
₹ 12,627.00
giving a profit of
₹ 2,627.00 (26.27%)
Note: Past profits do not guarantee future returns.
